文献速递造血干细胞移植与细胞治疗

CD52阴性T细胞预测基于阿仑单抗预处理方案后的急性移植物抗宿主病

CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen.
PubMed 文献 · Br J Haematol · 2020-05-14

该研究在69例接受含氟达拉滨、美法仑和阿仑单抗的减低强度预处理方案后行异基因造血干细胞移植的患者中分析T细胞亚群。结果显示CD52阴性T细胞及CD52阴性调节性T细胞的重建与急性移植物抗宿主病的发生、严重程度和临床病程相关;第+50天CD52阳性CD4阳性T细胞或CD52阳性调节性T细胞比例低于40%是急性移植物抗宿主病发生的风险因素。

要点

  • CD52阴性T细胞和CD52阴性调节性T细胞的重建与急性移植物抗宿主病的发生、严重程度及临床病程相关。
  • 发生急性移植物抗宿主病的患者CD52阳性T细胞水平显著低于慢性移植物抗宿主病或无移植物抗宿主病患者(P<0.001)。
  • 第+50天CD52阳性CD4阳性T细胞或CD52阳性调节性T细胞比例低于40%是急性移植物抗宿主病发生的风险因素。

核心结论

  • CD52阴性T细胞和CD52阴性调节性T细胞的重建是急性移植物抗宿主病发生的风险因素。

研究设计与样本

  • 研究纳入69例接受含氟达拉滨、美法仑和阿仑单抗的减低强度预处理方案后行异基因造血干细胞移植的患者,对T细胞亚群进行功能分析。

主要发现

  • CD52阴性T细胞和CD52阴性调节性T细胞的重建与急性移植物抗宿主病的发生、严重程度和临床病程相关。
  • 发生急性移植物抗宿主病的患者CD52阳性T细胞水平显著低于发生慢性移植物抗宿主病或无移植物抗宿主病的患者(P<0.001)。
  • 第+50天CD52阳性CD4阳性T细胞或CD52阳性调节性T细胞比例低于40%是急性移植物抗宿主病发生的风险因素。
  • CD52阴性调节性T细胞中糖蛋白A重复优势蛋白(GARP)水平显著降低(P<0.001),糖皮质激素诱导的TNFR相关蛋白(GITR)水平显著降低(P<0.001),趋化因子受体CXCR3水平显著降低(P=0.023),C-C趋化因子受体5型(CCR5)水平显著降低(P=0.004),而免疫球蛋白样转录本3(ILT3)水平升高(P=0.001),且抑制能力降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (HSCT) after a reduced-intensity conditioning (RIC) regimen with fludarabine, melphalan and alemtuzmab is an effective therapy for haematological malignancies. Alemtuzumab, a monoclonal antibody against CD52, a glycosylphosphatidylinositol-anchor-bound surface protein on lymphocytes, depletes T cells to prevent graft-versus-host disease (GVHD). Despite this, acute and chronic GVHD (a/cGVHD) remain life-threatening complications after HSCT. The aim of the present study was to identify parameters to predict GVHD. In 69 patients after HSCT, T-cell subsets were functionally analysed. Reconstitution of CD52neg T cells and CD52neg regulatory T cells (Tregs) correlated with onset, severity and clinical course of aGVHD. Patients with aGVHD showed significantly lower levels of CD52pos T cells compared to patients with cGVHD or without GVHD (P < 0·001). Analysis of T-cell reconstitution revealed a percentage of <40% of CD52pos CD4pos T cells or CD52pos Tregs at day +50 as a risk factor for the development of aGVHD. In contrast, CD52neg Tregs showed significant decreased levels of glycoprotein A repetitions predominant (GARP; P < 0·001), glucocorticoid-induced TNFR-related protein (GITR; P < 0·001), chemokine receptor (CXCR3; P = 0·023), C-C chemokine receptor type 5 (CCR5; P = 0·004), but increased levels of immunoglobulin-like transcript 3 (ILT3; P = 0·001), as well as a reduced suppressive capacity. We conclude that reconstitution of CD52neg T cells and CD52neg Tregs is a risk factor for development of aGVHD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Woelfinger P, Epp K, Schaefer L, et al. CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen. Br J Haematol. 2020. PMID: 32410220. doi:10.1111/bjh.16706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。